Antroquinonol is an orally administered small molecule, isolated from Antrodia camphorata, with anti-inflammatory and potential antiviral activity.
Dec 23 2021 |
et al., NCT04523181 | A Phase 2 Randomized, Double-blind, Placebo-controlled, Proof of Concept Study to Evaluate the Safety and Efficacy of Antroquinonol in Hospitalized Patients With Mild to Moderate Pneumonia Due to COVID-19 |
| 200% higher progression (p=1), 17% slower recovery (p=0.72), 2% shorter hospitalization (p=0.92), and 7% faster viral clearance (p=0.87). RCT 124 hospitalized COVID-19 patients showing no significant differences with antroquinonol. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.